ALPPS improves complete tumor removal in colorectal cancer study
ALPPS, or associating liver partition and portal vein ligation for staged hepatectomy, is a surgical technique designed to treat colorectal cancer that has metastasized to the liver. Compared with the standard two-stage hepatectomy, ALPPS increases the likelihood of successfully removing all liver tumors, though it shows little to no difference in long-term survival or the risk of death within 90 days of the procedure.
Key Clinical Takeaways:
- ALPPS improves the rate of complete tumor removal, successfully clearing all liver lesions in 92 out of 100 patients compared to 57 out of 100 in standard two-stage surgery.
- Clinical evidence up to December 4, 2025, indicates no significant difference in long-term survival or 90-day mortality between the two surgical approaches.
- The impact of ALPPS on quality of life and the incidence of serious complications remains uncertain due to limited data and small sample sizes in current research.
How the ALPPS technique differs from standard surgery
When colorectal cancer spreads to the liver, surgical removal of tumors remains the primary path to long-term survival. However, surgeons must ensure the remaining portion of the liver is large enough to function, or the patient risks liver failure. The standard two-stage hepatectomy involves an initial procedure to clear tumors from the future remnant of the liver while restricting blood flow to the portion slated for removal. This triggers the healthy liver tissue to grow, a process that can take four to six weeks. During this waiting period, many patients undergo chemotherapy, though some experience disease progression that prevents them from reaching the second stage of surgery.
In the first operation, the surgeon not only restricts blood flow but also physically divides the liver into two parts. This partition stimulates rapid growth of the healthy liver tissue, which may allow the second stage of the operation to occur during the same hospital stay. By shortening the growth interval, the technique aims to reduce the window of time during which the cancer might spread further.
What the Scandinavian study reveals about surgical outcomes
Researchers conducted a randomized study across three Scandinavian countries to compare these two methods. The trial included 100 participants, with 48 undergoing ALPPS and 49 receiving the standard two-stage hepatectomy. The results, updated as of December 4, 2025, suggest that while ALPPS is more effective at achieving complete tumor resection, it does not necessarily translate into a survival advantage.
Regarding long-term outcomes, the study found little evidence that ALPPS extends overall survival once the full treatment course is completed. The chance of the cancer recurring appears similar between the two groups. The following table summarizes the primary clinical findings observed in the study:
| Outcome Measure | ALPPS Group | Standard Two-Stage Group |
|---|---|---|
| Successful removal of all tumors | 92 out of 100 people | 57 out of 100 people |
| 90-day post-operative mortality | No significant difference | No significant difference |
| Long-term survival | No significant difference | No significant difference |
Why the impact on patient complications remains unclear
Assessing the safety profile of ALPPS presents challenges. The current evidence is limited by the small number of participants and the fact that patients were aware of which procedure they received, which may influence quality of life reporting. Because more patients in the ALPPS group successfully completed both stages of the surgery compared to the standard group, determining the true rate of serious complications is difficult; the standard group may appear to have higher complication rates simply because fewer patients reached the final stage of their planned treatment.
The absence of data from low- and middle-income countries further limits the generalizability of these findings.
What happens next in liver surgery research
The medical community continues to seek clarity on whether the rapid growth induced by ALPPS justifies the potential surgical risks. Future research requires larger, well-designed trials to establish whether the increased success rate in tumor removal translates into meaningful improvements in patient longevity or quality of life. Until such data becomes available, the choice between standard two-stage hepatectomy and ALPPS remains a decision dictated by the specific clinical presentation of the patient and the expertise available at the treating medical center.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.